Literature DB >> 27803106

EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells.

Shoumei Bai1, Patrick Ingram2, Yu-Chih Chen2, Ning Deng1, Alex Pearson1, Yashar S Niknafs1, Patrick O'Hayer1, Yun Wang1, Zhong-Yin Zhang3, Elisa Boscolo4, Joyce Bischoff5, Euisik Yoon2, Ronald J Buckanovich6,7.   

Abstract

Little is known about the factors that regulate the asymmetric division of cancer stem-like cells (CSC). Here, we demonstrate that EGFL6, a stem cell regulatory factor expressed in ovarian tumor cells and vasculature, regulates ALDH+ ovarian CSC. EGFL6 signaled at least in part via the oncoprotein SHP2 with concomitant activation of ERK. EGFL6 signaling promoted the migration and asymmetric division of ALDH+ ovarian CSC. As such, EGFL6 increased not only tumor growth but also metastasis. Silencing of EGFL6 or SHP2 limited numbers of ALDH+ cells and reduced tumor growth, supporting a critical role for EGFL6/SHP2 in ALDH+ cell maintenance. Notably, systemic administration of an EGFL6-neutralizing antibody we generated restricted tumor growth and metastasis, specifically blocking ovarian cancer cell recruitment to the ovary. Together, our results offer a preclinical proof of concept for EGFL6 as a novel therapeutic target for the treatment of ovarian cancer. Cancer Res; 76(21); 6396-409. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27803106      PMCID: PMC5120866          DOI: 10.1158/0008-5472.CAN-16-0225

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Expression of MAEG, a novel basement membrane protein, in mouse hair follicle morphogenesis.

Authors:  Aki Osada; Daiji Kiyozumi; Ko Tsutsui; Yuichi Ono; Charles N Weber; Nagisa Sugimoto; Toshio Imai; Akiko Okada; Kiyotoshi Sekiguchi
Journal:  Exp Cell Res       Date:  2005-02-01       Impact factor: 3.905

2.  Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation.

Authors:  H Gu; J C Pratt; S J Burakoff; B G Neel
Journal:  Mol Cell       Date:  1998-12       Impact factor: 17.970

3.  Highly-efficient single-cell capture in microfluidic array chips using differential hydrodynamic guiding structures.

Authors:  Jaehoon Chung; Young-Ji Kim; Euisik Yoon
Journal:  Appl Phys Lett       Date:  2011-03-21       Impact factor: 3.791

4.  Cloning of a novel epidermal growth factor repeat containing gene EGFL6: expressed in tumor and fetal tissues.

Authors:  G Yeung; J J Mulero; R P Berntsen; D B Loeb; R Drmanac; J E Ford
Journal:  Genomics       Date:  1999-12-01       Impact factor: 5.736

5.  In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.

Authors:  Gavin P Dunn; Hiu Wing Cheung; Pankaj K Agarwalla; Sapana Thomas; Yulia Zektser; Alison M Karst; Jesse S Boehm; Barbara A Weir; Aaron M Berlin; Lihua Zou; Gad Getz; Joyce F Liu; Michelle Hirsch; Francisca Vazquez; David E Root; Rameen Beroukhim; Ronny Drapkin; William C Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-02       Impact factor: 11.205

6.  Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2.

Authors:  Yun-Jung Choi; Patrick N Ingram; Kun Yang; Lan Coffman; Mangala Iyengar; Shoumei Bai; Dafydd G Thomas; Euisik Yoon; Ronald J Buckanovich
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

7.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Vasudeva Mahavisno; Radhika Varambally; Jianjun Yu; Benjamin B Briggs; Terrence R Barrette; Matthew J Anstet; Colleen Kincead-Beal; Prakash Kulkarni; Sooryanaryana Varambally; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

8.  Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.

Authors:  Shan Deng; Xiaojun Yang; Heini Lassus; Shun Liang; Sippy Kaur; Qunrui Ye; Chunsheng Li; Li-Ping Wang; Katherine F Roby; Sandra Orsulic; Denise C Connolly; Youcheng Zhang; Kathleen Montone; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

9.  Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.

Authors:  Heather L Pulaski; Gregory Spahlinger; Ines A Silva; Karen McLean; Angela S Kueck; R Kevin Reynolds; George Coukos; Jose R Conejo-Garcia; Ronald J Buckanovich
Journal:  J Transl Med       Date:  2009-06-19       Impact factor: 5.531

10.  Therapeutic potential of targeting the oncogenic SHP2 phosphatase.

Authors:  Li-Fan Zeng; Ruo-Yu Zhang; Zhi-Hong Yu; Sijiu Li; Li Wu; Andrea M Gunawan; Brandon S Lane; Raghuveer S Mali; Xingjun Li; Rebecca J Chan; Reuben Kapur; Clark D Wells; Zhong-Yin Zhang
Journal:  J Med Chem       Date:  2014-07-28       Impact factor: 7.446

View more
  31 in total

1.  Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages.

Authors:  Courtney A Penn; Kun Yang; Hong Zong; Jae-Young Lim; Alex Cole; Dongli Yang; James Baker; Sascha N Goonewardena; Ronald J Buckanovich
Journal:  Mol Cancer Ther       Date:  2017-11-13       Impact factor: 6.261

2.  Gene expression in regenerating and scarring tails of lizard evidences three main key genes (wnt2b, egfl6, and arhgap28) activated during the regulated process of tail regeneration.

Authors:  Massimo Degan; Luisa Dalla Valle; Lorenzo Alibardi
Journal:  Protoplasma       Date:  2020-08-27       Impact factor: 3.356

3.  Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.

Authors:  Shreya Raghavan; Pooja Mehta; Maria R Ward; Michael E Bregenzer; Elyse M A Fleck; Lijun Tan; Karen McLean; Ronald J Buckanovich; Geeta Mehta
Journal:  Clin Cancer Res       Date:  2017-08-16       Impact factor: 12.531

4.  Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer.

Authors:  Shoumei Bai; Sarah E Taylor; Mohd Azrin Jamalruddin; Stacy McGonigal; Edward Grimley; Dongli Yang; Kara A Bernstein; Ronald J Buckanovich
Journal:  Mol Cancer Ther       Date:  2022-09-06       Impact factor: 6.009

5.  Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.

Authors:  Kyunghee Noh; Lingegowda S Mangala; Hee-Dong Han; Ningyan Zhang; Sunila Pradeep; Sherry Y Wu; Shaolin Ma; Edna Mora; Rajesha Rupaimoole; Dahai Jiang; Yunfei Wen; Mian M K Shahzad; Yasmin Lyons; MinSoon Cho; Wei Hu; Archana S Nagaraja; Monika Haemmerle; Celia S L Mak; Xiuhui Chen; Kshipra M Gharpure; Hui Deng; Wei Xiong; Charles V Kingsley; Jinsong Liu; Nicholas Jennings; Michael J Birrer; Richard R Bouchard; Gabriel Lopez-Berestein; Robert L Coleman; Zhiqiang An; Anil K Sood
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

6.  EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.

Authors:  Jingnan An; Yi Du; Xuejun Fan; Yanhong Wang; Cristina Ivan; Xue-Guang Zhang; Anil K Sood; Zhiqiang An; Ningyan Zhang
Journal:  Oncogene       Date:  2018-11-19       Impact factor: 9.867

Review 7.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

8.  NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.

Authors:  Carrie D House; Elizabeth Jordan; Lidia Hernandez; Michelle Ozaki; Jana M James; Marianne Kim; Michael J Kruhlak; Eric Batchelor; Fathi Elloumi; Margaret C Cam; Christina M Annunziata
Journal:  Cancer Res       Date:  2017-10-26       Impact factor: 12.701

9.  High EGFL6 expression is associated with clinicopathological characteristics in colorectal cancer.

Authors:  Ying-Qing Cao; Zhe Li; Li-Feng Wang; Ning Li; Hong Chang
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

10.  Epidermal growth factor-like domain multiple 6 (EGFL6) promotes the migration and invasion of gastric cancer cells by inducing epithelial-mesenchymal transition.

Authors:  Fu-Chun Huo; Wen-Tao Zhu; Xu Liu; Yun Zhou; Lan-Sheng Zhang; Jie Mou
Journal:  Invest New Drugs       Date:  2020-09-19       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.